无抽搐电休克联合抗精神病药物治疗难治性精神分裂症的临床观察

目的探讨无抽搐电休克（MECT）联合抗精神病药物治疗难治性精神分裂症的临床疗效和安全性。方法 58例难治性精神分裂症患者自药物治疗4周起加用MECT治疗12周。采用阳性与阴性症状量表（PANSS）和治疗中出现的副反应量表（TESS）评定疗效和不良反应;采用韦氏记忆量表（WMS）评定MECT对记忆力的影响。结果 MECT治疗后PANSS评分明显降低,WMS评分在治疗结束后1d明显降低,1周及2周时恢复。第16周末,总有效率82.76%。结论 MECT联合抗精神病药物治疗难治性精神分裂症的疗效显著,不良反应少,虽对记忆力有一定影响,这种影响是短暂的,可逆的。

A Clinical Study of Antispychotics Plus Modified Electroconvulsive Therapy in Treatment Refractory Schizophrenia

Objective To understand the efficacy and safety of antispychotics plus modified electroconvulsive therapy（MECT） in treatment of refractory schizophrenia.Methods 58 patients with refractory schizophrenia who had received antipsychotic medication for 4 weeks were assigned to receive MECT for 12 weeks,Clinical efficacies were assessed with the Positive and Negative Syndrome Scale（PANSS） and adverse effects were assessed with the Treatment Emergent Symptoms Scale（TESS） and impact on memory was assessed with Wechsler Memory Scale（WMS）.Results The PANSS scores decreased significantly after MECT.The WMS scores decreased significantly at 1 day after the endpoint of MECT,but there was no significant difference between before and after 1、2 weeks of endpoint of MECT.At the end of the 16th week,The total rate of effectiveness was 82.76%.Conclusion Antipsychotics plus MECT has significant effectiveness in treatment resistant schizophrenia,and has little adverse effects.even if it has transcient impact on memory which is reversible.